# EDGAR Filing Document

**Accession Number:** 0001692415
**File Stem:** 0001493152-23-002116
**Filing Date:** 2023-1
**Character Count:** 18083
**Document Hash:** c34c9d694006f6f7aa8428cb1bd5d5cb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-002116.hdr.sgml**: 20230123

**ACCESSION NUMBER**: 0001493152-23-002116

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20230123

**DATE AS OF CHANGE**: 20230123

**EFFECTIVENESS DATE**: 20230123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Co-Diagnostics, Inc.
- **CENTRAL INDEX KEY:** 0001692415
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 462609396
- **STATE OF INCORPORATION:** UT
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269350
- **FILM NUMBER:** 23542480

**BUSINESS ADDRESS:**
- **STREET 1:** 4049 SOUTH HIGHLAND DRIVE
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84124
- **BUSINESS PHONE:** 8012789769

**MAIL ADDRESS:**
- **STREET 1:** 4049 SOUTH HIGHLAND DRIVE
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84124

**As filed with the Securities and Exchange Commission on January 23, 2023**

Registration No. 333-237684

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER THE SECURITIES ACT OF 1933**

**CO-DIAGNOSTICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Utah** | **46-2609396** |
| (State or other jurisdiction of | (IRS Employer |
| incorporation or organization) | Identification No.) |

---

**2401 S. Foothill Drive**

**Salt Lake City, Utah 84109**

(Address of Principal Executive Offices)

**Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan**

(Full Title of the Plan)

**Brian Brown**

**Chief Financial Officer**

**Co-Diagnostics, Inc.**

**2401 S. Foothill Drive**

**Salt Lake City, Utah 84109**

**(385) 831-7576**

(Name, Address and Telephone Number, including area code, of Agent for Service)

**With copies to:**

**Kevin Ontiveros, Esq.**

**General Counsel**

**2401 S. Foothill Drive**

**Salt Lake City, Utah 84109**

**Telephone: (801) 450-7001**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☐ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (this "**Registration Statement**") is filed by Co-Diagnostics, Inc. (the "**Registrant**") for the purpose of registering an additional 6,000,000 shares of the Registrant's common stock, par value $0.001 per share (the "**Common Stock**") to be reserved for issuance under the Registrant's Amended and Restated 2015 Long Term Incentive Plan (the "**2015 Plan**"), which increase of additional shares were approved by the Registrant's board of directors and by the Registrant's shareholders.

Pursuant to General Instruction E of Form S-8, the contents of the Registration Statement on Form S-8 of the Registrant filed with the Securities and Exchange Commission (the "**Commission**" or "**SEC**") on April 15, 2020 (Registration No. 333-237684) including any amendments thereto, such as the amendment filed on November 20, 2020, or filings incorporated therein, are incorporated herein by this reference to the extent not replaced hereby.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information specified in Items 1 and 2 of Part I of this Registration Statement is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933 (the "**Securities Act**") and the introductory note to Part I of Form S-8. The document(s) containing the information specified in Part I of Form S-8 will be sent or given to each employee who is eligible to participate in the Plan, as required by Rule 428 under the Securities Act. Such documents need not be filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.**

The following documents, which have been filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), are incorporated herein by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 Company's Annual Report on Form [10-K](https://www.sec.gov/Archives/edgar/data/1692415/000149315222007662/form10-k.htm) for the fiscal year ended December 31, 2021, filed with the SEC on March 24, 2022;

(b) The
 Company's Quarterly Reports on Form 10-Q for the fiscal quarters ended [March 31, 2022](https://www.sec.gov/Archives/edgar/data/1692415/000149315222013020/form10-q.htm) , [June 30, 2022](https://www.sec.gov/Archives/edgar/data/1692415/000149315222022072/form10-q.htm) ; and [September 30, 2022](https://www.sec.gov/Archives/edgar/data/1692415/000149315222031350/form10-q.htm) ;

(c) The
 Company's Current Reports on Form 8-K filed on [April 1, 2022](https://www.sec.gov/Archives/edgar/data/1692415/000149315222008865/form8-k.htm) , [May 12, 2022](https://www.sec.gov/Archives/edgar/data/1692415/000149315222013017/form8-k.htm) , [June 16, 2022](https://www.sec.gov/Archives/edgar/data/1692415/000149315222016975/form8-k.htm) , [August 11, 2022](https://www.sec.gov/Archives/edgar/data/1692415/000149315222022067/form8-k.htm) , [September 2, 2022](https://www.sec.gov/Archives/edgar/data/1692415/000149315222024979/form8-k.htm) , and [November 10, 2022](https://www.sec.gov/Archives/edgar/data/1692415/000149315222031335/form8-k.htm) ; and

(d) The
 description of the Registrant's common stock contained in the Registrant's Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1692415/000147793217003234/axdx_8a12b.htm) filed with
 the Commission on July 11, 2017 pursuant to Section 12(b) of the Exchange Act, including any subsequently filed amendments and reports
 updating such description.

All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8.** **Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br> **Number** | **Exhibit Description** | **Filed with this**<br> **Report** | **Incorporated by**<br> **Reference herein from Form or Schedule** | **Filing Date** | **SEC File/Reg.**<br> **Number** |
| 4.1 | [Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1692415/000147793217000164/filename2.htm) |  | Draft Registration Statement (Exhibit 3.1) | 01/12/17 | 377-01467 |
| 4.1.1 | [Amendment to the Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1692415/000147793217000164/filename3.htm) |  | Draft Registration Statement (Exhibit 3.1.1) | 01/12/17 | 377-01467 |
| 4.1.2 | [Articles of Amendment to Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1692415/000149315219000111/ex3-2.htm) |  | Form 8-K (Exhibit 3.2) | 01/03/19 | 001-38148 |
| 4.1.3 | [Articles of Amendment](https://www.sec.gov/Archives/edgar/data/1692415/000149315222007662/ex3-1_3.htm) |  | Form 10-K (Exhibit 3.1.3) | 03/24/22 | 001-38148 |
| 4.2 | [Amended and Restated Bylaws of Co-Diagnostics, Inc.](https://www.sec.gov/Archives/edgar/data/1692415/000149315222008865/ex3-1.htm) |  | Form 8-K (Exhibit 3.1) | 04/01/22 | 001-38148 |
| 4.4 | [Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan](https://www.sec.gov/Archives/edgar/data/1692415/000149315220022110/ex4-1.htm) |  | Form S-8/A | 11/20/20 | 333-237684 |
| 5.1 | [Opinion of Legal Counsel](ex5-1.htm) | X |  |  |  |
| 23.1 | [Consent of Independent Registered Public Accounting Firm,](ex23-1.htm) | X |  |  |  |
| 23.2 | [Consent of Counsel (included in Exhibit 5.1)](ex5-1.htm) |  |  |  |  |
| 24.1 | [Power of Attorney (included in signature page)](#CIDX_001) |  |  |  |  |
| 107 | [Filing Fee Table](ex107.htm) | X |  |  |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Salt Lake City, Utah, on this 23 day of January, 2023.

---

| | |
|:---|:---|
| **CO-DIAGNOSTICS, INC.** | **CO-DIAGNOSTICS, INC.** |
| BY: | */s/ Dwight Egan* |
|  | Dwight Egan |
|  | President and Chief Executive Officer |

---

Each person whose signature appears below constitutes and appoints Dwight Egan and Brian Brown, and each of them singly, her or his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution in each of them singly, for her or him and in her or his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Co-Diagnostics, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as she or he might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Dwight Egan* | Chief Executive Officer, President and Director | January 23, 2023 |
| Dwight Egan | (Principal Executive Officer) |  |
| */s/ Brian Brown* | Chief Financial Officer | January 23, 2023 |
| Brian Brown | (Principal Financial and Accounting Officer) |  |
| */s/ Eugen Durenard* | Director | January 23, 2023 |
| Eugene Durenard |  |  |
| */s/ Edward Murphy* | Director | January 23, 2023 |
| Edward Murphy |  |  |
| */s/ James Nelson* | Director | January 23, 2023 |
| James Nelson |  |  |
| */s/ Richard Serbin* | Director | January 23, 2023 |
| Richard Serbin |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

Life Science Law PC

Kevin Ontiveros *Direct Dial* (801 450-7001 kontiveros@lifesciencelawpc.net

January 23, 2023

Co-Diagnostics, Inc.

2401 S. Foothill Drive

Salt Lake City, Utah 84109

Ladies and Gentlemen:

We have acted as legal counsel to Co-Diagnostics, Inc., a Utah corporation (the "Company"), in connection with the preparation and filing with the United States Securities and Exchange Commission (the "Commission") of a Registration Statement on Form S-8 (the "Registration Statement"), pursuant to which the Company is registering the issuance under the Securities Act of 1933, as amended (the "Securities Act"), of an additional 6,000,000 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), that may be issued pursuant to the Company's 2015 Long Term Incentive Plan (the "2015 Plan"). This opinion is being rendered in connection with the filing of the Registration Statement with the Commission. All capitalized terms used herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.

We have examined such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purposes of our opinions set forth below. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed the legal capacity for all purposes relevant hereto of all natural persons. As to questions of fact material to our opinions, we have relied upon certificates or comparable documents of officers and other representatives of the Company and of public officials.

Our opinion is limited to the laws of the State of Utah. We express no opinion as to the effect of the law of any other jurisdiction. Our opinion is rendered as of the date hereof, and we assume no obligation to advise you of changes in law or fact (or the effect thereof on the opinions expressed herein) that hereafter may come to our attention.

Based upon the foregoing, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the 2015 Plan, will be validly issued, fully paid and non-assessable.

We understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act, and we hereby consent thereto.

Life Science Law PC \| 4372 W Mille Lacs Dr, South Jordan, UT 84009 \|Direct: (801) 981-8420 \| Mobile: (801) 450-7001 \|

Life Science Law PC

Co-Diagnostics, Inc.

January 23, 2023

---

| |
|:---|
| Sincerely, |
| */s/ LSLAW* |

---

Life Science Law PC \| 4372 W Mille Lacs Dr, South Jordan, UT 84009 \|Direct: (801) 981-8420 \| Mobile: (801) 450-7001 \|

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Co-Diagnostics, Inc.

Salt Lake City, Utah

We hereby consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan of our report dated March 24, 2022, relating to the consolidated financial statements of Co-Diagnostics, Inc., and subsidiaries (collectively, the Company), appearing in the Annual Report on Form 10-K of the Company as of December 31, 2021 and for the year then ended.

*/s/ HAYNIE & COMPANY*

Salt Lake City, UT

January 20, 2023

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Co-Diagnostics, Inc.**

(Exact Name of Registrant as Specified in its Charter)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security<br> Type** | **Security Class<br> Title** | **Fee<br> Calculation<br> or Carry<br> Forward<br> Rule** | **Amount<br> Registered (1)** | **Proposed<br> Maximum<br> Offering<br> Price Per<br> Share (2)** | **Maximum<br> Aggregate<br> Offering<br> Price (2)** | **Fee Rate** | **Amount of<br> Registration<br> Fee (2)** |
| **Fees to Be Paid** | Equity | Common Stock, $0.001 par value | Other | 6000000 | $2.83 | $16980000 | 0.00011020 | $1871.20 |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $16980000 |  | $1871.20 |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  | $0 |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $0 |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $1871.20 |

---

(1) Pursuant
 to Rule 416(a) under the Securities Act of 1933, as amended (the "**Securities Act** "), this Registration Statement
 shall also cover any additional shares of the Registrant's common stock that become issuable under the Registrant's Amended
 and Restated 2015 Long Term Incentive Plan (the "**2015 Plan**") in respect of the securities identified in the above
 table by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without the Registrant's
 receipt of consideration that increases the number of the outstanding shares of the Registrant's common stock.

(2) Pursuant
 to Rules 457(c) and (h) under the Securities Act, the proposed maximum offering price per share and the proposed maximum aggregate
 offering price are estimated for the purpose of calculating the amount of the registration fee and are based on the average of the
 high and low sales price of the Registrant's common stock as reported on the Nasdaq Capital Market on January 19, 2023.